Speaker: Zhiying Li, PhD

GemPharmatech has created a unique and translationally relevant humanized Fc gamma receptor (hFcgR) mouse model to advance immunotherapy drug development. FcgRs play a vital role in how monoclonal antibodies (mAbs) activate and promote various immune responses (e.g., the antibody-dependent cellular cytotoxicity (ADCC) mechanism, antibody-dependent cellular phagocytosis (ADCP)) in a tumor microenvironment. Another immunotherapy drug development approach being investigated by oncology researchers is blocking FcgRs with antagonists to minimize resistance and increase activity of mAbs. Our hFcgR mice are created by replacing the endogenous murine FcgR genes (Fcgr1, Fcgr2b, Fcgr3, Fcgr4) with the human FcgR genes (FCGR1, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCGR3B). During this webinar our experts will discuss:

• The role of FcgRs in innate immunity

• The differences between murine and human FcgRs

• The need for more translationally relevant animal models that recapitulate the human condition

• How our hFcgR mouse model can accelerate and improve your immunotherapy drug development for cancer